Robust isolation of malignant plasma cells in multiple myeloma.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.

Detaljer

Författare
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Hematologi
Originalspråkengelska
Sidor (från-till)1336-1340
TidskriftBlood
Volym123
Utgivningsnummer9
StatusPublished - 2014
PublikationskategoriForskning
Peer review utfördJa

Relaterad forskningsoutput

Christophersen, M. K., 2017 feb 22, Lund: Lund University, Faculty of Medicine. 94 s.

Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

Visa alla (1)

Related projects

Visa alla (1)